Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, December 02, 2020
WuXi Advanced Therapies announced the completion of a facility expansion that will triple its advanced testing capacity at the company's Philadelphia Navy Yard campus.
read more
Thursday, February 28, 2019
WuXi Biologics congratulates its strategic partner Amicus Therapeutics on receiving FDA Breakthrough Therapy Designation for AT-GAA (ATB200/AT2221).
read more
WuXi Biologics has received FDA pre license inspection (PLI) approval for its MFG8 drug substance manufacturing facility in Hebei, clearing the way for commercial supply of a potential blockbuster autoimmune therapy.
read more
WuXi Biologics said its MFG17 drug substance facility at the Shanghai Fengxian site has successfully completed its first GMP production campaign, with manufacturing executed without any deviations.
read more
WuXi Biologics and Immune Pharmaceuticals announced a development and manufacturing agreement for the production of bertilimumab, Immune's first-in-class anti-eotaxin-1 monoclonal antibody.
read more
Thursday, January 16, 2020
WuXi Biologics and Almirall announced the signing of a strategic collaboration agreement enabling Almirall to leverage the proprietary WuXiBody™ platform to develop bispecific antibodies for dermatological diseases.
read more
WuXi Biologics announced that its Biosafety Testing Center in Suzhou has successfully passed a Good Manufacturing Practice (GMP) inspection by the European Medicines Agency (EMA) with zero critical findings.
read more
Thursday, August 01, 2024
WuXi Biologics announced that four manufacturing facilities and Suzhou Biosafety Testing Center in China have received Good Manufacturing Practice (GMP) certificates from the European Medicines Agency (EMA), demonstrating the company's commitment to ...
read more
Wednesday, March 21, 2018
WuXi Biologics has selected 4,000 liter (L) Custom Single Run (CSR) disposable bioreactors from ABEC for its new commercial manufacturing facility (MFG4) in Wuxi city, Jiangsu, China.
read more
Wednesday, January 31, 2024
WuXi Biologics announced the successful completion of the first manufacturing run at its drug substance facility MFG7, paving the way for large-scale commercial manufacturing projects at this Ireland site.
read more
WuXi Biologics announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub.
read more
WuXi Biologics has entered into a strategic partnership LOI with a global vaccine leader, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market.
read more
Friday, February 14, 2020
WuXi Biologics has released the following statement addressing the Coronavirus outbreak.
read more
Wednesday, February 09, 2022
We have been made aware of a recent U.S. Commerce Department announcement that two WuXi Biologics (Cayman) subsidiaries in Shanghai and Wuxi will be added to the department's "Unverified List" (UVL) on February 8, 2022.
read more
Wednesday, April 15, 2026
WuXi Biologics has obtained ISO 13485:2016 Medical Device Quality Management System certification, following an on-site audit that concluded with zero non-conformities.
read more